Supply Chain Intelligence

Bicycle Therapeutics plc Supply Chain

BCYC supply chain intelligence for Bicycle Therapeutics plc: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

BCYC ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

6Suppliers
20Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Bicycle Therapeutics plc (BCYC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

30Total relationships
3Distinct source URLs
11High confidence
0.746Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Bicycle Therapeutics plc Suppliers

TickerNameConfidenceEvidence
CONTRACT-MANUFACTURING-ORGANIZATIONS CONTRACT-MANUFACTURING-ORGANIZATIONS 90% The Company has entered into various agreements with contract manufacturing organizations to provide clinical trial materials
CONTRACT-RESEARCH-ORGANIZATIONS CONTRACT-RESEARCH-ORGANIZATIONS 90% The Company has entered into various agreements with contract research organizations to provide clinical trial services
VENDORS VENDORS 90% The Company has entered into various agreements with vendors for preclinical research studies, synthetic chemistry and other services for operating purposes
ECKERT-ZIEGLER ECKERT-ZIEGLER 80% We are developing a pipeline of novel binders with optimized properties for radioisotope delivery. In October 2024, first human imaging data for a BRC molecule targeting MT1-MMP was presented by the …
CRBP Corbus Pharmaceuticals Holdings, Inc. 72% Reciprocal relationship from CRBP graph: designed to be an improved next-generation site-specific Nectin-4 targeting antibody drug conjugate. CRB-701 is a monoclonal antibody attached to an MMAE cyto…
RNA Atrium Therapeutics, Inc. 72% Reciprocal relationship from RNA graph: ss of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies; • our ability to obtain and maintai…

Bicycle Therapeutics plc Customers

TickerNameConfidenceEvidence
BAYER-CONSUMER-CARE-AG BAYER-CONSUMER-CARE-AG 90% Our revenue to date has been primarily generated from our research collaborations with Bayer Consumer Care AG, or Bayer, Novartis Pharma AG, or Novartis, Ionis Pharmaceuticals, Inc., or Ionis, and Ge…
IONIS-PHARMACEUTICALS-INC IONIS-PHARMACEUTICALS-INC 90% Our revenue to date has been primarily generated from our research collaborations with Bayer Consumer Care AG, or Bayer, Novartis Pharma AG, or Novartis, Ionis Pharmaceuticals, Inc., or Ionis, and Ge…
NOVARTIS-PHARMA-AG NOVARTIS-PHARMA-AG 90% Our revenue to date has been primarily generated from our research collaborations with Bayer Consumer Care AG, or Bayer, Novartis Pharma AG, or Novartis, Ionis Pharmaceuticals, Inc., or Ionis, and Ge…
HTGC Hercules Capital, Inc. 72% arch and development of our product candidates and preclinical programs, raising capital and providing general and administrative support for our operations. To date, we have financed our operations …
HTGC Hercules Capital, Inc. 72% Reciprocal relationship from HTGC graph: Reciprocal relationship from BCYC graph: arch and development of our product candidates and preclinical programs, raising capital and providing general and ad…
IONS Ionis Pharmaceuticals, Inc. 72% al for these product candidates, manufacturing, marketing and selling those products for which we, or any of our collaborators, may obtain marketing approval, satisfying any post-marketing requiremen…
IONS Ionis Pharmaceuticals, Inc. 72% Reciprocal relationship from IONS graph: Reciprocal relationship from BCYC graph: al for these product candidates, manufacturing, marketing and selling those products for which we, or any of our coll…
LLY Eli Lilly and Company 72% dministered, the radiopharmaceuticals are designed to target tumor antigens that are unique to, or preferentially expressed on, cancer cells throughout the body. We believe the advantages of Bicycle …
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from BCYC graph: dministered, the radiopharmaceuticals are designed to target tumor antigens that are unique to, or preferentially expr…
ALL-WALES-MEDICINES-STRATEGY-GROUP ALL-WALES-MEDICINES-STRATEGY-GROUP 62% n assessing health technologies, including new medicinal products, and providing the basis for cooperation at the level of the European Union for joint clinical assessments in these areas. The Regula…
BAYER-NOVARTIS-PHARMA-AG BAYER-NOVARTIS-PHARMA-AG 62% al for these product candidates, manufacturing, marketing and selling those products for which we, or any of our collaborators, may obtain marketing approval, satisfying any post-marketing requiremen…
BICYCLERD-LIMITED BICYCLERD-LIMITED 62% tents The Company is subject to risks common to companies in the biotechnology and pharmaceutical industries, including but not limited to, risks of delays in initiating or continuing research progra…
BICYCLETX-LIMITED BICYCLETX-LIMITED 62% tents The Company is subject to risks common to companies in the biotechnology and pharmaceutical industries, including but not limited to, risks of delays in initiating or continuing research progra…
BICYCLETX-LIMITED-BICYCLERD-LIMITED BICYCLETX-LIMITED-BICYCLERD-LIMITED 62% data used by management; and (v) evaluating the reasonableness of the significant assumption used by management in estimating of the level of service performed on a sample of contracts. Evaluating ma…
CANCER-RESEARCH-TECHNOLOGY-LIMITED CANCER-RESEARCH-TECHNOLOGY-LIMITED 62% rogram #1 performance obligations will be satisfied over the next one to two years , and the remaining deferred revenue allocated to the LSR Go Option for Collaboration Program #1 will commence reven…
CAPITAL-RESOURCES CAPITAL-RESOURCES 62% e months ended March 31. 2025, which was primarily due to a decrease in interest income of $3.5 million due to lower average interest rates as well as lower cash and cash equivalents balances period …
COMPANY-CORBUS-PHARMACEUTICAL-HOLDINGS-INC COMPANY-CORBUS-PHARMACEUTICAL-HOLDINGS-INC 62% dministered, the radiopharmaceuticals are designed to target tumor antigens that are unique to, or preferentially expressed on, cancer cells throughout the body. We believe the advantages of Bicycle …
COORDINATION-GROUP COORDINATION-GROUP 62% dministered, the radiopharmaceuticals are designed to target tumor antigens that are unique to, or preferentially expressed on, cancer cells throughout the body. We believe the advantages of Bicycle …
MABWELL-THERAPEUTICS-INC MABWELL-THERAPEUTICS-INC 62% dministered, the radiopharmaceuticals are designed to target tumor antigens that are unique to, or preferentially expressed on, cancer cells throughout the body. We believe the advantages of Bicycle …
NOVARTIS-IONIS-PHARMACEUTICALS-INC NOVARTIS-IONIS-PHARMACEUTICALS-INC 62% al for these product candidates, manufacturing, marketing and selling those products for which we, or any of our collaborators, may obtain marketing approval, satisfying any post-marketing requiremen…

Bicycle Therapeutics plc Debt Obligations

InstrumentDescriptionConfidenceEvidence
BCYC-DEBT Debt stack $30.9M 90% Market cache reports total debt of $30.9M.
BCYC-DEBT-8115 Xbrl Convertible 90% xbrl convertible detail from xbrl 2019-12-31.
BCYC-DEBT-8114 Warrants outstanding: 92885 90% xbrl warrant detail from xbrl 2020-12-31.

Bicycle Therapeutics plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Bicycle Therapeutics plc.

Bicycle Therapeutics plc Ownership

HolderNameConfidenceEvidence
BCYC-OWNER-BAKER-BROS-ADVISORS-LP BAKER BROS. ADVISORS LP 90% 13F overlay lists BAKER BROS. ADVISORS LP as top holder; 100 tracked holders.

Bicycle Therapeutics plc Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
ALEC Alector, Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CPRX Catalyst Pharmaceuticals, Inc. 100.00 2
ALT Altimmune, Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AKTS Aktis Oncology, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
VEEV Veeva Systems Inc. 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
CAPR Capricor Therapeutics, Inc. 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
NVO Novo Nordisk A/S 100.00 2
IRON Disc Medicine, Inc. 100.00 2
BYSI BeyondSpring Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Bicycle Therapeutics plc.

Unlock full BCYC data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
BCYC
Unlock BCYC Supply Chain Data
Verified relationships include:
CONTRACT-MANUFACTURING-ORGANIZATIONSCONTRACT-MANUFACTURING-OR…Supplier90%
CONTRACT-RESEARCH-ORGANIZATIONSCONTRACT-RESEARCH-ORGANIZATIONSSupplier90%
BAYER-CONSUMER-CARE-AGBAYER-CONSUMER-CARE-AGCustomer90%
IONIS-PHARMACEUTICALS-INCIONIS-PHARMACEUTICALS-INCCustomer90%
+26 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →